Merck to Acquire Eyebiotech for $1.3 Billion Upfront, Adding Clinical-Stage Retinal Therapy Restoret

According to foreign media reports, informed sources stated that Merck will acquire Eyebiotech, an ophthalmic biotechnology company, for $1.3 billion in cash, with the announcement expected as early as the 29th local time. Under the terms of the agreement, Merck may also pay up to $1.7 billion in milestone payments for Eyebiotech. Eyebiotech's retinal disease treatment drug, Restoret, is currently in the clinical stage. (Jiemian)Original Link